✦ LIBER ✦

Monoclonal antibody studies of epidermal growth factor receptor

✍ Scribed by GREGORIOU, M; REES, A

Book ID: 122330312
Publisher: Elsevier Science
Year: 1983
Tongue: English
Weight: 343 KB
Volume: 7
Category: Article
ISSN: 0309-1651
DOI: 10.1016/0309-1651(83)90167-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

120 Monoclonal antibody therapy in endom

120 Monoclonal antibody therapy in endometriosis — study of inhibitory effect of anti-epidermal growth factor receptor antibody

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 464 KB

Preclinical studies predicting low clini

Preclinical studies predicting low clinical toxicity of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) nimotuzumab

✍ Angel Casacó; Nuris Ledón; Normando Iznaga-Escobar; Maria Elena Arteaga; Tania C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Phase II study of nimotuzumab, a humaniz

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

✍ Dirk Strumberg, Beate Schultheis, M. E. Scheulen, R. A. Hilger, J. Krauss, N. Ma 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 144 KB

1247 Phase I study of nimotuzumab, a hum

1247 Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in Japanese patients with solid tumors

✍ N. Boku; K. Yamazaki; A. Fukutomi; T. Takahashi; N. Yamamoto; M. Miyazaki; T. Sa 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

291 Dose repeated toxicity study of the

291 Dose repeated toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (Theracim) by endovenous route in cercopithecus aethiops sabaeus monkeys

✍ A. Casacó; M. Arteaga-Pérez; M. Maceira; O. Hernández-Sosa; A. Bada-Barro; A. Le 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB